CONTINEUM THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.74 USD | -2.27% |
|
+1.48% | 0.00% |
| Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
| Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 404.9 | - | - |
| Enterprise Value (EV) 1 | 201.2 | 345.1 | 335.3 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | 27 x | - |
| EV / Revenue | - | 23 x | - |
| EV / EBITDA | -4.64 x | -7.41 x | -4.67 x |
| EV / FCF | -5.44 x | -8.22 x | -4.93 x |
| FCF Yield | -18.4% | -12.2% | -20.3% |
| Price to Book | - | -8.76 x | 6.97 x |
| Nbr of stocks (in thousands) | 25,131 | - | - |
| Reference price 2 | 16.11 | 16.11 | 16.11 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | 15 | - |
| EBITDA 1 | - | -43.33 | -46.6 | -71.78 |
| EBIT 1 | - | -45.95 | -40.9 | -80.07 |
| Operating Margin | - | - | -272.64% | - |
| Earnings before Tax (EBT) | 23.17 | - | - | - |
| Net income | 22.72 | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| FCF margin | - | - | -280% | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -9.93 | -9.5 | -12.6 | -15.7 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/16/24 | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 204 | 59.7 | 69.5 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| ROE (net income / shareholders' equity) | - | - | - | -663% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share 2 | - | - | -1.840 | 2.310 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.43 | 0.35 | 0.55 |
| Capex / Sales | - | - | 2.34% | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.11
USD
Average target price
28
USD
Spread / Average Target
+73.81%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 405M | |
| +69.48% | 62.86B | |
| -0.76% | 41.38B | |
| +45.66% | 40.38B | |
| -10.72% | 27.64B | |
| +14.42% | 26.46B | |
| -22.34% | 18.9B | |
| +4.81% | 12.67B | |
| +23.65% | 12.27B | |
| +28.25% | 12.07B |
- Stock Market
- Equities
- CTNM Stock
- Financials Contineum Therapeutics, Inc.
